Abstract
Background: It is difficult for some patients to keep taking TS-1 at the proposed four weeks administration followed by a two-week rest because of its side effects. When TS-1 is given for five days followed by a two-day rest (five days on/two days off), the drug concentration is almost equal to that of the proposed regimen, but TS-1 can be taken longer without deterioration of its clinical effect. Aim: The purpose of this study was to retrospectively analyze the effect and safety of TS-1 given at a five-day on/two-day off> regimen in metastatic breast cancer. Methods: Twenty-five HER-2 negative patients were recruited between 2006 and 2014 at our hospital. Median age was 68 (44-87), PS 0/1/2 was 8/10/7 cases, ER positive/negative was 15/10 cases, and there was no prior chemotherapy after recurrence in 25 cases. TS-1 was administered at a dose of 80-120mg/day at a five-day on/two-day off> regimen. Results: Median treatment duration was 25 weeks (3-114 weeks), CR/PR/SD/PD clinical response was shown in 0/8/10/7 cases, and response rate was 32%. Five of ten SD patients could maintain the regimen for more than 24 weeks. In terms of hematologic toxicity, anemia was shown in one case, and there were no cases of neutropenia. In terms of non- hematologic toxicity, no severe side effects were shown. Discontinuance was observed in only one case because of diarrhea. Conclusion: A five-day on/two-day off> regimen of TS-1 in metastatic breast cancer is well tolerated, and it can be continually given to elderly patients or those with poor PS without reducing QOL, making TS-1 an effective metronomic treatment.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call